Acquisitions and Collaborative Agreements (Narrative) (Details) (USD $)	3 Months Ended							3 Months Ended
	Mar. 31, 2013		Mar. 31, 2012	Feb. 14, 2013 SMS Pharmaceuticals Ltd.	Feb. 27, 2013 Agila Specialties Private Limited	Feb. 27, 2013 Committed Financing Agila Specialties Private Limited	Feb. 27, 2013 Maximum Agila Specialties Private Limited	Mar. 31, 2013 Generics Segment SMS Pharmaceuticals Ltd.		Mar. 31, 2013 Biocon Insulin Products
Business Acquisition [Line Items]
Research and development expense	$ 126,486,000		$ 80,959,000							$ 20,000,000
Total purchase consideration				32,000,000	1,600,000,000	1,000,000,000
Goodwill, acquired during period	10,213,000	[1]						10,213,000	[1]
Contingent consideration							$ 250,000,000

[1] See Note 4.